Interestingly, the patient diagnosed with papillary carcinoma, showed a unique drug response pattern, including erdafitinib (a fibroblast growth factor receptor inhibitor), dexamethasone, (an immunomodulatory agent) and PF-00562271, (a focal adhesion kinase (FAK) inhibitor). This evidence concerns the gene PTK2 and papillary carcinoma.